← back to ranking

PFE · Pfizer Inc.

Drug Manufacturers - General · mkt cap $145.6B · calls: Q1 FY2026 vs Q4 FY2025
42.0 conviction · conf-adj 42

conf –

enthusiasm:21.0 · trend:-5 · quantifies:0 · impact:0 · under_radar:14 · credibility:5 · business_impact:4 · disruption:0 · commitment:0 · confirmation:3

Enthusiasm latest 7 / prev 8 (falling)

Pfizer frames AI as a companywide productivity and innovation lever, with the strongest claimed use cases in R&D cycle-time compression, manufacturing planning, commercial targeting, and personalized content. Credibility is moderate because management links AI to concrete functions and ongoing deployment, but it does not quantify revenue, savings, margin, or productivity impact from AI. The latest call still calls AI strategic, but provides less operational detail than Q4 FY2025, so enthusiasm appears lower.

PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

55/100 track record   too-early  6 calls reviewed

Pfizer talks about AI on nearly every call (drug discovery, marketing targeting, manufacturing, cost savings) but almost entirely qualitatively; the only clean quantified AI-specific target is the late, forward-looking 1,200-GPU buildout, which is not yet judgeable, and the one AI-linked savings figure is bundled into a broader cost program — so there is no matured AI promise to grade and the track record is genuinely too-early.

Expand AI compute capacity to more than 1,200 GPUs over the next two years, largely for R&D AI applications — promised Q4 FY2025
too-early By Q1 FY2026 Pfizer reiterated enterprise-wide AI embedding across R&D, commercial and manufacturing, but the two-year window had only just begun and no GPU or progress metric was reported
Additional $1.2B in net cost savings, partly by leveraging digital tools including automation and AI — promised Q1 FY2025
too-early Folded into the broader cost-realignment program (tracking to ~$7.2B total net savings by end of 2026, reported on track in Q1 FY2026); AI is only one of several levers so the AI-specific contribution is not isolable
PRICED-IN (REFINED)
LOW (room left)

Est. revisions falling  ·  Fwd P/E 8.2  ·  EV/Sales 3.3x

AI claim maps to Biopharma Segment

Estimate signals are falling: recent price targets are below last-quarter and last-year averages, while forward revenue and EPS estimates decline across 2025-2027. The stock is not trading at a rich AI premium, with an 8.2x forward P/E and 3.3x EV/Sales for a mature pharma company. Any AI-driven drug-discovery, clinical, or commercial efficiency upside would most plausibly flow through the Biopharma Segment, and the combination of falling estimates plus non-stretched valuation suggests that upside is not already priced in.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
7Q4 FY20242Q1 FY20254Q2 FY20251Q3 FY20258Q4 FY20252Q1 FY2026

AI enthusiasm across 6 calls — trend → flat

AI appeared in concrete bursts around commercial/R&D productivity and scaling plans, but was not sustained across consecutive calls.

RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY

6/10 qualitative impact   moderate  medium-term · soft evidence

Where AI matters: R&D productivity, manufacturing planning, commercial targeting

Pfizer is deploying AI across R&D, manufacturing, commercial, and enterprise workflows, with the most plausible upside from faster discovery/development decisions and better resource productivity. The opportunity could be meaningful, but evidence is still mostly qualitative, with no AI-attributable revenue, savings, cycle-time, or pipeline-output metrics yet.

Caveats: AI impact is bundled into broader cost and productivity programs, making attribution weak; Drug discovery and clinical-development benefits may take years to show up in approved products; Competitors can access similar AI tools, limiting durable differentiation; Regulatory, data-quality, and model-validation constraints could slow deployment

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 1/10

AI does not directly commoditize Pfizer's core model of regulated drug development, clinical evidence, IP, manufacturing scale, and commercialization. It may raise competitive intensity in discovery, but it is more likely to be an industry productivity tool than a deflator of Pfizer's revenue units.

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $951M · beta 0.305 · px $25.55

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Confirming — insiders neutral, institutions adding, management language 6/10 measured.
INSIDERS neutral no open-market buys/sells in last 6mo (routine: 48 awards, 19 tax-withholding)
INSTITUTIONS (13F) adding as of 2026-03-31: 255 new / 240 closed positions; 1545 increased / 1084 reduced; institutional ownership +0.25pp; +6 net 13F holders
MGMT LANGUAGE 6/10 measured AI is explicitly strategic and enterprise-wide, but language stays qualitative with promise/opportunity framing and no quantified impact.
commit “Embedding the use of artificial intelligence across our company is a key strategic priority”
commit “we are driving continued progress in R&D, commercial, manufacturing and core enterprise functions”
commit “Leveraging the power of AI to compress timelines and improve decision-making is central to our innovation strategy”
VERBATIM AI QUOTES
“Embedding the use of artificial intelligence across our company is a key strategic priority, and we are driving continued progress in R&D, commercial, manufacturing and core enterprise functions.”
— Albert Bourla, Q1 FY2026
“We are empowering our colleagues to accelerate innovation by pairing frontier AI tools, tailored to function and role, with comprehensive and continuously updated training.”
— Albert Bourla, Q1 FY2026
“One of the areas where we see the most substantial promise is the discovery, development and delivery of new medicines and vaccines.”
— Albert Bourla, Q1 FY2026
“Leveraging the power of AI to compress timelines and improve decision-making is central to our innovation strategy.”
— Albert Bourla, Q1 FY2026
“We are embedding AI into each functional line of R&D.”
— Albert Bourla, Q1 FY2026
“Pfizer has a vast repository of small and large molecule, translational and clinical data and AI is creating the opportunity to unlock insights that could drive a significant impact on how we discover and develop medicines and vaccines.”
— Albert Bourla, Q1 FY2026
“We think that right now, in the next few years, it is the time to execute on AI transformation of these organizations.”
— Albert Bourla, Q1 FY2026
“And finally, we are scaling artificial intelligence across R&D, manufacturing, commercial, and patient engagement to improve productivity and accelerate innovation.”
— Albert Bourla, Q4 FY2025
“We have been setting the foundation with AI already, data agenda workflows, and compute capacity.”
— Albert Bourla, Q4 FY2025
“To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.”
— Albert Bourla, Q4 FY2025
“In R&D, we are embedding AI across discovery, development, regulatory, and medical to increase productivity and accelerate the pipeline and timelines.”
— Albert Bourla, Q4 FY2025
“AI is optimizing supply planning and manufacturing, contributing to our manufacturing optimization program goals.”
— Albert Bourla, Q4 FY2025
“In commercial, AI is helping to accelerate new product launches, delivering insights for dynamic targeting, and supporting personalized messaging and real-time marketing content.”
— Albert Bourla, Q4 FY2025
“Actually, we'd increase of programs is going to be by deploying AI, which already happened, in 2025 with excellent results.”
— Albert Bourla, Q4 FY2025
“That creates significant productivity gains.”
— Albert Bourla, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Umer Raffat): First, I guess, what's the likelihood that Pfizer entertains a transformative M&A in near or medium term, which could end up impacting dividend as we've seen in history?
A: Albert Bourla: "We think that right now, in the next few years, it is the time to execute on AI transformation of these organizations. And that requires not the disruption of mega merger."
Q (Q4 FY2025, Courtney Breen): And then kind of combining that with the element you just raised, Albert, of the AI investment, the 1,200 GPU deployment that you're making, kind of when and where we begin to see impact from that strategy, and will that impact anything in the operations of R&D of those pivotal trials, or should we be thinking more about innovation on the research side of the long run?
A: Dave Denton: "So we're being able to be more productive in the infrastructure across R&D and take on more sub to be able to focus on creating medicines for the end of the decade and beyond. So I think what we're trying to do is continue to refresh, improve the productivity across our R&D platform to invest those dollars back into R&D to continue to forward advance the programs that we have underway and the programs that we're developing."